文献速递细菌感染、耐药与抗菌药物医院感染防控

抗击多重耐药肺炎克雷伯菌:当前治疗方案与未来方向

Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

本文综述多重耐药肺炎克雷伯菌治疗策略进展,包括双药和三药联合方案,分析blaKPC、blaNDM和mcr基因全球传播及孔蛋白突变、外排泵过表达和酶降解等耐药机制。评估联合治疗证据与单药治疗争议,并指出吸入抗生素递送(尤其干粉吸入器)作为靶向肺部给药策略的潜力与障碍。

要点

  • 联合方案如多黏菌素/美罗培南双药及多黏菌素B/美罗培南/利福平三药,优于单药的证据存在争议。
  • 耐药机制包括blaKPC、blaNDM和mcr基因及孔蛋白突变、外排泵过表达和酶降解,存在地域差异。
  • 吸入抗生素(尤其干粉吸入器)有望实现肺部靶向高浓度并减少全身毒性。

核心结论

  • 多重耐药肺炎克雷伯菌治疗需综合联合方案与新型递送策略,吸入抗生素是未来重点方向。

研究设计与样本

  • 综述,分析当前治疗策略(双药和三药联合)的临床疗效与局限性,并讨论耐药机制全球传播及吸入抗生素递送。

主要发现

  • 耐药决定因子blaKPC、blaNDM和mcr基因全球传播,耐药机制包括孔蛋白突变、外排泵过表达和酶降解且存在地域差异。
  • 双药(多黏菌素/美罗培南)和三药(多黏菌素B/美罗培南/利福平)联合方案的证据被分析,其优于单药治疗存在争议。
  • 吸入抗生素递送尤其干粉吸入器可实现靶向有效肺部药物浓度并减少全身毒性。

关键数值与推荐

  • 联合方案包括双药(多黏菌素/美罗培南)和三药(多黏菌素B/美罗培南/利福平)。
  • 耐药基因包括blaKPC、blaNDM和mcr。

临床怎么用

  • 临床可考虑联合治疗方案,但需注意其优于单药的证据存在争议。
  • 吸入抗生素尤其干粉吸入器是靶向肺部给药的有前景策略。

局限性

  • 吸入抗生素面临制剂稳定性、监管障碍和临床试验持续短缺等显著障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Klebsiella pneumoniae is a major cause of hospital-acquired pneumonia and a critical global threat due to its escalating multidrug resistance. This review highlights current advancements in therapeutic strategies, including double and triple drug combinations, and evaluates their clinical efficacy and limitations. We discuss the global dissemination of resistance determinants such as blaKPC, blaNDM and mcr genes, and the complex mechanisms, including porin mutations, efflux pump overexpression and enzymatic degradation. The regional variation in these mechanisms undermines treatment success. Evidence for antibiotic combination therapy, including the double (colistin/meropenem) and triple (polymyxin B/meropenem/rifampicin) regimens, is analysed, along with controversies regarding their superiority over monotherapy. Finally, we highlight inhaled antibiotic delivery, particularly dry powder inhalers, as a promising strategy to achieve targeted, effective pulmonary drug concentrations and reduced systemic toxicity. Despite progress, significant barriers remain, including formulation stability, regulatory hurdles and the continued shortage of clinical trials. Future research should prioritize optimizing inhaled drug therapies and innovative delivery platforms to combat multidrug-resistant K. pneumoniae lung infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Islam R, Das SC, Pletzer D, et al. Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions. J Antimicrob Chemother. 2026. PMID: 41734205. doi:10.1093/jac/dkag064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。